From: Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
 |  | MDS | MDS-AML | MDS post-treatment | |||
---|---|---|---|---|---|---|---|
 |  | RA | RCMD | RAEB-1 | RAEB-2 | ||
Patients (N) | Â | 18 | 10 | 14 | 13 | 20 | 16 |
Gender | Â | Â | Â | Â | Â | Â | Â |
 | Male | 5 | 6 | 9 | 7 | 10 | 10 |
 | Female | 13 | 4 | 5 | 6 | 10 | 6 |
Age (year) | Â | Â | Â | Â | Â | Â | Â |
 | Median | 36 | 48.5 | 69 | 65 | 68.5 | 53 |
 | Range | 22-72 | 20-77 | 52-81 | 25-82 | 28-82 | 22-74 |
BM Blast (%) | Â | Â | Â | Â | Â | Â | Â |
 | Median | 1 | 1.75 | 6.5 | 15.5 | 55 | 0.75 |
 | Range | 0-3.5 | 0.5-4.5 | 5-8.5 | 11-19.5 | 23-98 | 0-7.5 |
Karyotype (N)* | Â | Â | Â | Â | Â | Â | Â |
 | Good | 14 | 7 | 7 | 4 | 5 | 13 |
 | Intermediate | 4 | 2 | 2 | 0 | 3 | 3 |
 | Poor | 0 | 1 | 5 | 9 | 12 | 0 |
IPSS score | Â | Â | Â | Â | Â | Â | Â |
 | Median | 0.5 | 0.5 | 1.25 | 3 | –– | –– |
 | Range | 0-1 | 0-1.5 | 1-2 | 2-3 | –– | –– |